CANbridge Life Sciences Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2012-06-12
- Employees
- 101
- Market Cap
- -
Clinical Trials
4
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Phase 2 Study of CAN008 in Subjects With GBM
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT05447195
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03746288
CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma
- Conditions
- Glioblastoma
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT03152708
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT02853565
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Linkou, Taipei, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
News
No news found